Goldman Sachs analyst Salveen Richter upgraded Ionis Pharmaceuticals (IONS) to Neutral from Sell with a price target of $65, up from $45. The firm says Ionis is transitioning to a commercial growth story and has optimized its antisense oligonucleotide technology. The positive Phase 3 Tryngolza data in severe hypertriglyceridemia showed a significant impact on the key acute pancreatitis endpoint, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $80 from $78 at Barclays
- Ionis Pharmaceuticals price target raised to $86 from $71 at Morgan Stanley
- Ionis Pharmaceuticals price target raised to $83 from $81 at BofA
- Ionis Pharmaceuticals price target raised to $92 from $90 at Guggenheim
- Buy Rating for Ionis Pharmaceuticals: Promising Phase 3 Results for Zilganersen in Alexander Disease